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PURPOSE: To investigate the influence of dark chocolate (DC) supplementation on 
resting and steady state exercise metabolism in a group of recreationally fit/athletic 
females. METHODS: Using a randomized, double-blind design, 18 exercise trained 
female subjects were assigned to a 30-d supplementation with either 20g d-1 of 70% DC 
(n = 9) or a calorically matched white chocolate (WC) (n = 9). Prior to supplementation 
(PRE), subjects underwent indirect calorimetry assessment for resting energy expenditure 
(REE) followed by an assessment of exercise energy expenditure (EEE) consisting of 
steady state cycling for 20 min, 10 min at 50 watts (EEE-50) and 10 min at 100 watts 
(EEE-100). Upon completion of the 30-d supplementation (POST), subjects repeated the 
assessment for REE-0, EEE-50, and EEE-100. All data are presented as mean (SE). 
RESULTS: Pre-supplementation REE (DC 1455 ± 49, WC 1566 ± 49 kcal d-1, p ≥ .05), 
EEE-50 (DC 4.85 ± 0.15, WC 4.60 ± 0.15 kcal  min-1), and EEE-100 (DC 7.06 ± 0.16, 
WC 6.76 ± 0.16 kcal min-1) were not significantly different between groups (p ≥ .05). 
Post supplementation REE was significantly increased by 9.5% in the DC group (Δ REE: 
DC 138 ± 21, WC -30 ± 21 kcal d-1, p = .001).  Neither EEE-50 (DC 4.48 ± 0.16, WC 
4.47 ± 0.16 kcal min-1) nor EEE-100 (DC 6.50 ± 0.17, WC 6.63 ± 0.17 kcal min-1) were 
significantly different between groups (p ≥ .05). There was no significant difference 
within or between group time effects for substrate utilization at rest or during EEE-50 or 
EEE-100 (p ≥ .05).  CONCLUSION: To our knowledge this is the first study to 
demonstrate that a relatively small daily dosage of DC can significantly elevate REE but 
does not impact steady state EEE or substrate utilization in a group of athletically fit 
females. 
 ii
* Product was provided by The Hershey Company, Hershey, Pennsylvania.  
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Chocolate is considered to be a delicacy by many cultures today, and its 
popularity is increasing exponentially.  Chocolate provides the income for more than 40 
million individuals yielding approximately 4.2 million tons of cocoa worth $11.8 billion 
(Beg, Ahmad, Jan, & Bashir, 2017).  This literature review will discuss the origins of 
chocolate and how it became the dessert that the world enjoys today in the 21st century; 
how chocolate is processed from a bitter nut to a sweet delicacy; the different types of 
chocolate and their nutritional content (Latif, 2013), and epicatechin health effects (Hurst 
et al., 2011).  In the 16th-19th centuries, people believed that chocolate could heal various 
disease or emotional states such as cancer, nervousness, and flatulence (Dillinger et al., 
2000).  As the years progressed, DC was suggested to assist with heart disease, 
Alzheimer’s disease, and central adiposity (Petyaev & Bashmaokv, 2017).  With the 
increased interest in athletics, research has started to test DC for performance enhancing 
effects.  Research has suggested that DC reduces oxidative stress (Morillas-Ruiz et al., 
2005; Morillas-Ruiz, Garcia, Lopez, Vidal-Guevara, & Zafrilla, 2006), resting blood 
pressure (Grassi, Lippi, Necozione, Desideri, & Ferri, 2005), and time to fatigue 
(Nogueira et al., 2011).  Dark chocolate has also been shown to stimulate lipid catabolism 
(Venables, Hulston, Cox, & Jeukendrup, 2008), insulin sensitivity (Grassi, Lippi, 
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Necozione, Desideri, & Ferri, 2005), maximal oxygen uptake and exercise power output 







REVIEW OF LITERATURE 
History 
Chocolate has been an item of reverence and worship by some Latino cultures for 
quite some time.  Cacao was first discovered by the Mayas, Incas, and Aztecs in Central 
America (Dillinger et al., 2000).  Before cacao was consumed as candy, it was originally 
drunk as a hot, bitter beverage with cocoa powder, cinnamon, and pepper (Verna, 2013).  
This was only consumed by royal or important adult men such as priests, government 
officials, military officers, and decorated warriors.  Cacao was known to be intoxicating, 
valuable, and significant, thus, women and children were not allowed to partake.  
However, there was one other group who was allowed to consume cacao and that was 
prisoners before they faced their death (Dillinger et al., 2000).  According to the Aztec’s 
creation story, the god Quetzalcoatl (Feather Serpent) found cacao in a mountain.  
Because of this divine discovery, priests offered it to many other deities by pouring their 
own blood from their earlobes onto the cacao and this was deemed as a worthy sacrifice 
for the gods.  In keeping with this practice, they fed their prisoners cacao before they 
sacrificed them to the gods, who would deem it as an acceptable sacrifice.  Thus, cacao 
was known to be the food of the gods (Coe & Coe, 1996). 
In 1502, Columbus was the first European to discover cacao, and explorers from 
other countries soon followed after him in his discovery (Dillinger et al., 2000).  
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Columbus found that cacao was roasted into an almond like bean and used as currency.  
While Cortez, a Spaniard, found that Montezuma drank cocoa before he would go meet 
with his wives.  By 1544, the cocoa beverage was introduced into the Spanish courts and 
within a century, all of Western Europe was experiencing chocolate in high demand.  For 
instance, France founded plantations in the Caribbean, and Spain settled their plantations 
in the Philippines so they could meet the demand of cocoa consumption in their home 
lands.  (Dillinger et al., 2000)  
In the 16th-19th centuries, cocoa was not only consumed because of its delectable 
aroma and flavor, but because of its purported medicinal functions.  In the early 16th 
century in Mesoamerica, medicinal treatment was based off of a hot/cold system called 
allopathy.  Diseases that are perceived as hot were treated using cold foods or medicines 
and vice versa.  It was observed that foods such as chili peppers, rhubarb, and vanilla 
were used by Mexicans as a purgative and cocoa was used as a laxative.  Cocoa was also 
used to treat stomach and intestinal discomfort.  For the Mexicans who had phlegm, they 
would mix a drink of opossum tail and follow it with a hot beverage of cocoa which had 
been mixed with three herbs: piper sanctum, chiranthodendron pentadactylon, and vanilla 
planifolia.  In addition, cocoa was added as a flavoring agent for medicines.  Some other 
medical conditions that were treated with cocoa were angina, constipation, tartar removal, 
dysentery, gout, heart attack, hemorrhoids, and lactation difficulties.  (Dillinger et al., 
2000) 
The Western Europeans used chocolate to treat angina, belching, and flatulence in 
the same fashion as the Mexican culture, and additionally used cocoa to treat liver 
disease, menstrual irregularity, strengthening of the heart, heart palpitations, 
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hypochondria, inflammation, insomnia, cancer, probability of conception, hangovers, 
vaginal irritation, toothaches, scurvy, antidote against poison, nervousness, old age, and 
the list goes on (Dillinger et al., 2000).  However, Hernández (1577) first recorded that 
even though there were a lot of medicinal uses for cocoa, it could cause obesity because 
of the sugar and the fatty oils that were used in the preparation of the drink.  Conversely, 
if someone were underweight, chocolate was considered to be a viable option to promote 
weight gain (Dillinger et al., 2000).  In the 20th century, cocoa was still used for some of 
the same disease states or discomforts that were used during the previous century, but 
also included treatment for hemorrhoids, cracked skin, sores, and bronchitis.  It was 
advised that caution be used when treating children and anxious individuals because it 
was believed to cause excitation (Dillinger et al., 2000).   
The Cacao Tree and Bean 
  The cacao tree has long and wide leaves with oblong fruit, starts bearing fruit 
about 5 years of age, and reaches maximal reproduction in approximately 10 years.  It 
grows the best at 10-20 degrees north and south of the equator, an area which is 
commonly known as the cocoa belt.  The fruit on the cacao tree is called a pod or a 
cabosside, shaped like a melon, with a variety of colors ranging from brown/yellow to 
purple.  Each pod contains approximately 20-40 cacao beans and each plant produces 20-
50 cabossides each year with 10 cabossides yielding one kilogram of cocoa.  The taste of 





Varieties of Chocolate 
Before the seeds are harvested, they are known as cacao beans; however, after 
they are roasted and grounded, they are then known as cocoa.  Cocoa and chocolate are 
two distinctive food products.  Cocoa is comprised of non-fat, finely ground cacao beans.  
Chocolate is cocoa powder combined with cocoa butter and sugar (Lippi et al., 2008).  
There are three different types of chocolates: white, milk, and dark.  White chocolate has 
cocoa butter, milk, and sugar with no cocoa solids.  Milk chocolate is high in milk fat 
with sugar and up to 10% cocoa bean solids.  Dark chocolate contains cocoa butter and 
up to 80% cocoa bean solids (Petyaev & Bashmakov, 2017). 
Nutrition Content and Bioavailability 
The fat content in DC is known as cocoa butter.  It is 33% oleic acid 
(monounsaturated), 33% stearic acid (saturated), and 25% palmitic acid (saturated).  
Oleic acid has been shown to have a positive effect on blood lipid levels; whereas stearic 
acid, most commonly associated with the saturated fat found in animal products, has been 
demonstrated to increase plasma LDL-cholesterol, triglyceride levels, blood pressure, and 
the risk for coronary vascular disease (CVD) (Latif, 2013).  However, there is not enough 
research to suggest that the stearic acid from the cacao bean impacts plasma lipids in the 
same manner as it does from animal fat (Latif, 2013).  Palmitic acid, which is a saturated 
fat, has been thought to be associated with heart disease and cancer.  However, these 
suggestions are unclaimed and not conclusive (Fattore & Fanelli, 2013). 
Polyphenols have been widely used to help reduce oxidative stress especially in 
the field of athletics.  Cocoa flavonoids have been suggested to have the highest 
concentration of polyphenols suggesting that cocoa and DC could provide the greatest 
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health benefits, specifically with regards to the vasodilator and anti-inflammatory 
properties (Decroix et al., 2017).  Cocoa has a significantly greater flavonoid content than 
tea, wine, and milk chocolate (Latif, 2013).  Other foods that contain flavonoids include 
apples, berries (Rodriguez-Mateos, et al., 2015), green and black tea, grapes, olives, DC, 
hazelnuts, and pecans (Decroix et al., 2017).  Dark chocolate is high in flavonoids which 
include epicatechins and catechins.  The bioavailability (absorption rate) is the greatest in 
(-)-epicatechins versus catechins, and a lipid environment promotes absorption rate in the 
small intestine within 2-4 hours of ingestion (Petyaev & Bashmakov, 2017).  However, 
the more processed (drying, roasting, and fermentation) the DC, the less (-)-epicatechin 
content; however, the processing is necessary to reduce the bitterness and improve the 
palatability of the final product (Hurst et al., 2011; Petyaev & Bashmakov, 2017).   
Medicinal Uses 
Dark chocolate ingestion has been shown to promote vasodilation, stimulate 
cerebral blood flow, improve oxygen and glucose delivery, and decrease some of the 
symptoms associated with Alzheimer’s disease (Petyaev & Bashmaokv, 2017).  Cocoa 
has also been reported to play an important role in synaptic function, neuronal growth, 
memory, anti-inflammatory, mood, and cognitive function (Petyaev & Bashmaokv, 
2017).  Varela et al. (2017) suggests that the (-)-epicatechin, found in cocoa, can promote 
the browning of fat which can increase fatty acid metabolism via the formation of new 
mitochondria.  G-protein coupled estrogen receptors (GPER) have been shown to have a 
significant effect in muscle cells thereby stimulating the effects of (-)-epicatechins on 
mitochondrial biogenesis and skeletal muscle anabolism (Moreno-Ulloa et al., 2015).  
Cocoa flavonoids have, also, been shown to decrease high sensitivity C-reactive proteins 
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which reduce inflammation and reduce aggregatory effects of platelets (Hamed et al., 
2008).   
There have been concerns from the lay population with chocolate consumption 
and weight gain.  However, research suggests that moderate DC consumption has been 
shown to decrease adiposity in European adolescents (Petyaev & Bashmaokv, 2017) and 
has not been associated with obesity (Petyaev & Bashmakov, 2017).  Dark chocolate has 
also been shown to reduce the absorption of lipids and carbohydrates thereby improving 
insulin sensitivity, hypoglycemia (Petyaev & Bashmaokv, 2017), and plasma LDL 
cholesterol levels (Tokede, Gaziano & Diousse, 2011).  Despite the evidence, some 
individuals are unwilling to consume DC, for reasons such as a dislike for taste, flavor, 
texture, and aroma, or the belief that it is fattening and unhealthy (Dillinger et al., 2000). 
Athletic Application 
The polyphenols found in DC have been shown to reduce exercise induced 
oxidative stress (Morillas-Ruiz et al., 2005; Morillas-Ruiz, Garcia, Lopez, Vidal-
Guevara, & Zafrilla, 2006; Lyall et al., 2009; Peake, Suzuki, & Coombes, 2007; Powers, 
Quindry, & Hamilton, 2004), inflammatory response (Lyall et al., 2009; Peake, Suzuki, 
& Coombes, 2007; Powers, Quindry, & Hamilton, 2004), and muscle fatigue and 
immunosuppression (Peake, Suzuki, & Coombes, 2007; Powers, Quindry, & Hamilton, 
2004).  (-)-Epicatechins have also been shown to stimulate lipid catabolism and fat 
oxidation (Venables et al., 2008), and endurance capacity via increased mitochondrial 
biogenesis (Davis, Carlstedt, Chen, Carmichael, & Murphy, 2010).  Dark chocolate was 
demonstrated to positively impact arterial and endothelial function (Vlachopoulos et al., 
2005), resting blood pressure and insulin sensitivity (Grassi, Lippi, Necozione, Desideri, 
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& Ferri, 2005), high-density lipoprotein (HDL) concentration (Mursu et al., 2004), 
resting and post exercise plasma levels of oxidative stress markers (Davison, Callister, 
Williamson, Cooper & Gleeson, 2011; Allgrove, Farrell, Gleeson, Williamson, & 
Cooper, 2011), plasma free fatty acids during exercise and a lower respiratory exchange 
ratio (RER) (Allgrove et al., 2011).  Gutierrez-Salmean et al. (2014) suggested that the 
consumption of (-)-epicatechin twice a day increased follistatin (promoter of muscle 
growth) and decreased myostatin (suppressor of muscle growth).  Nogueira et al. (2011) 
suggested (-)-epicatechins reduced muscle fatigue, improved treadmill performance, and 
increased muscle capillarity.  Findings of Taub et al. (2016) indicated that three months 
of DC consumption increased VO2max, cycling power output, mitochondrial function, 
plasma HDL cholesterol concentration, and decreased oxidative stress. 
Summary 
The effects of DC consumption indicate association with improvements in 
cardiovascular health, maximal oxygen consumption, cycling power output, 
mitochondrial function, and decrease in oxidative stress.  Even though it has a greater 
energy content, a moderate DC consumption has not been associated with weight gain or 
central adiposity.  However, it has been associated with an elevation of mood, a decrease 








Chocolate is considered a delicacy by many cultures and provides income for 
more than 40 million individuals annually yielding approximately 4.2 million tons of 
cocoa worth $11.8 billion (Beg, Ahmad, Jan, & Bashir, 2017).  It has been enjoyed for 
centuries because of its rich and delectable flavor and its purported health benefits such 
as a reduction in oxidative stress, inflammation, and physical fatigue (Decroix et al., 
2017).  Flavonoids, naturally occurring polyphenolic plant compounds, are an active 
component of cocoa to which many of its health benefits are often attributed (Decroix et 
al., 2017).  Flavonoid rich foods include wine, milk chocolate (Latif, 2013), apples, 
berries (Rodriguez-Mateos, et al., 2015), green and black teas, grapes, olives, DC, 
hazelnuts, and pecans (Decroix et al., 2017).   
Moderate DC consumption has been reported to promote arterial vasodilation and 
cerebral blood flow, enhance oxygen and glucose delivery, and improve cognitive 
function (Petyaev & Bashmaokv, 2017).  It has also been shown to decrease fat 
deposition in adolescents (Petyaev & Bashmaokv, 2017), low density lipoprotein (LDL) 
cholesterol, high sensitivity C-reactive proteins, and inflammation and platelet 
aggregation (Hamed et al., 2008; Lyall et al., 2009; Tokede, Gaziano, and Diousse, 
2011).  Dark chocolate has been shown to stimulate insulin sensitivity and hypoglycemic 
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control (Petyaev & Bashmaokv, 2017), and lipid oxidation (Venables, Hulston, Cox, & 
Jeukendrup, 2008).  Contrary to contemporary thought, moderate DC consumption has 
not been shown to be associated with obesity (Petyaev & Bashmakov, 2017).   
The flavanol (-)-epicatechin, found in high concentration in cocoa, has been 
shown, in a mouse model, to reduce skeletal muscle fatigue, improve treadmill 
performance, and increase muscle capillary density (Noguiera et al., 2011).  These 
findings are supported by Taub et al. (2016) who indicated that three months of DC 
consumption by humans may decrease oxidative stress and improve maximal oxygen 
uptake, cycling power output, mitochondrial function, and high-density lipoprotein 
(HDL) concentration.   
Considering the recent health and physiological exercise performance benefits 
attributed to the administration of (-)-epicatechin and supplementation of (-)-epicatechin-
rich cocoa products, the purpose of this study was to investigate the influence of 70% DC 
supplementation on REE and steady state EEE.  We investigated a relatively small 
dosage of DC (20g d-1) for a short duration (~30 d) in a group of recreationally 
fit/athletic females. 
Methods 
The study employed a randomized double blind, placebo-controlled design and 
was approved by the Institutional Review Board for the use of Human Subjects in 
Research (IRB 03572-2017) (Appendix A & B).  Inclusion criteria were non-smoking, 
normal weight females (body mass index 18.5-25 kg m2), 18-30 years of age, performing 
a minimum of 5 h wk-1 of moderate- to high-intensity exercise.  Twenty-five subjects 
met the inclusion criteria; however, seven were eventually excluded due to factors such 
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as dislike of chocolate, non-compliance with supplementation, or incurring a physical 
injury during the course of the study that limited their ability to continue.  This left a final 
subject pool of n = 18.  There were no reported adverse events associated with the study.  
Subjects were instructed to maintain their normal physical activity levels throughout the 
duration of the study.   
Each subject was required to arrive in the laboratory on three separate occasions 
over ~35 days.  The first visit was a preliminary/familiarization assessment, the second 
session was a pre-supplementation assessment, and the final session was a post-
supplementation assessment.   
Preliminary/familiarization assessment.  The preliminary/familiarization assessment 
required subjects to arrive to the laboratory 3-4 hours post-prandial and having refrained 
from intense exercise for 48-h prior.  Upon arrival, subjects completed an informed 
consent and physical activity and health history questionnaire (Appendix D), and were 
assessed for resting measures of body weight, height, heart-rate, and blood pressure.  
Resting energy expenditure (REE) was assessed via open-circuit indirect calorimetry 
(Vmax Encore Metabolic Cart; Yorba Linda, CA) (Appendix E).  Flow volume and gas 
calibrations were performed prior to each testing session according to the manufacturer’s 
instructions.  Subjects were asked to remove their shoes, assume a supine position on an 
examination table, and a Plexiglas ventilated hood was placed over their head.  Expired 
gases were then assessed for ~30-min.  The first 10-min allowed the subject to acclimate 
to the test and reach a metabolic steady state.  The REE was determined from 10-min of 
steady state respiratory gas measurements assessed during min 10-30.  During this time, 
the flow pump rate was manipulated to insure a FECO2 between .75-.85.  Energy 
 13 
expenditure was calculated from an abbreviated Weir equation [3.9(VO2) + 1.1(VCO2) x 
1.44] (Weir, 1949).  
Upon completion of the assessment of REE, the metabolic cart was immediately 
recalibrated to accommodate exercise testing, and the subject was fitted with a facemask 
and mask flow sensor (Appendix F & H).  The subject then performed 20-min of 
continuous exercise on a Velotron cycle (Racermate, Seattle, WA) (Appendix G) with the 
first 10-min performed at 50 watts and the last 10-min performed at 100 watts.  Expired 
gas volumes and content were analyzed and used in the assessment of EEE and substrate 
utilization.  Cycling cadence was selected by each subject and then replicated during 
subsequent sessions.    
Pre-supplementation assessment.  The pre-supplementation assessment was scheduled 
~7-d after the preliminary/familiarization assessment and ~14-d after the onset of their 
last menstrual cycle to control for fluctuations in metabolic rate (Solomon, Kurzer, & 
Calloway, 1982).  Subjects then performed another assessment for REE and 20-min of 
cycling with 10-min each at 50 and 100 watts.  Upon completion of the second visit, each 
subject was provided 14-d of supplementation.  
Post-supplementation assessment.  The post-supplementation assessment was performed, 
as closely as possible, to the same day of their menstrual cycle as performed during the 
pre-supplementation assessment.  The post-supplementation assessment consisted of 
resting and exercise energy expenditure in the same fashion as described in the pre-
supplementation assessment.  
Supplementation.  Supplementation was assigned using a randomized, double-blind 
design.  The experimental treatment consisted of 20 g of 70% DC (Scharffen Berger 
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Baking Chunks or Squares, The Hershey Company, Hershey, PA) and the placebo 
consisted of a calorically matched volume of WC (White Chocolate Baking Chips, The 
Hershey Company, Hershey, PA).  Supplementation duration was initially scheduled for 
a total of 28 days; however, in an effort to minimize the influence of the menstrual cycle 
on metabolic rate, the duration was individualized for each subject (Solomon et al., 
1982).  An individual not affiliated with the project was responsible for the preparation of 
the supplementation.  Each day’s chocolate was individually wrapped in foil and placed 
into a plastic bag with 7 days in each plastic bag for a total of 4-5 bags for each 
participant.  These were then placed in single brown paper bags to disguise the content 
from the investigators.  Additionally, subjects were informed that the purpose of the 
study was to investigate the effect of chocolate on metabolic rate; however, they were not 
aware that the intent of the study was to investigate the effect of DC on metabolic rate 
and that the WC was a placebo.  To our knowledge, there was no communication 
between subjects.   
Subjects were instructed to consume their prescribed chocolate and to return in 
14-d to receive the other 14-d of assigned supplementation.  At this time subjects were 
questioned regarding compliance with the supplement ingestion protocol and those 
unable, or unwilling, to comply were excluded from further participation in the study.  
During the supplementation period, subjects were instructed to refrain from the 
consumption of high flavonoid containing foods such as extra chocolate, blueberry, 
cherry, strawberry, blackberry, raspberry, apple, pomegranate fruits and/or products, 
chestnuts, hazelnuts, black tea, green tea, and red wine. Additionally, subjects were 
instructed to not consume their prescribed chocolate with any dairy product (i.e. yogurt, 
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sour cream, milk, cottage cheese, cheese, and butter/margarine) 1-h before and after 
consumption of supplementation since dairy.  There are conflicting reports on the 
influence of dairy on the bioavailability of flavonoids, so we chose a conservative 
approach to restrict dairy use with the consumption of the chocolate (Lippi et al., 2008; 
Roura et al., 2007).   
Statistical analyses were performed using Statistical Packaging for the Social 
Sciences (SPSS).  A 2 X 2 mixed design ANOVA (Treatment: WC vs. DC; Time: pre-
supplementation vs. post-supplementation) was used to assess differences within and 
between conditions for REE, EEE, and substrate oxidation rates.  The significance level 
was set at p < .05.  All data are presented as mean ± SE.   
Results 
Demographics.  Inclusion criteria were non-smoking, normal weight females (body mass 
index 18.5-25 kg m2), 18-30 years of age, performing a minimum of 5 h wk-1 of 
moderate- to high-intensity exercise.  Twenty-five subjects met the inclusion criteria; 
however, seven were eventually excluded due to factors such as dislike of chocolate, non-
compliance with supplementation, incurring a physical injury during the course of the 
study that limited their ability to continue, or data was an outlier.  This left a final subject 
pool of n = 18.  Subjects reported no adverse effects with supplementation.  The duration 
of supplementation for each group was not significantly different (DC 30.8 ± 2.6, WC 





TABLE 1. Subjects’ Characteristics. 
 
 WC (n = 9) DC (n = 9) 
Body weight (kg) 69.5 ± 11.7 71.6 ± 11.8 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 
BMI (kg•m2) 23.4 ± 2.2 25.0 ± 3.3 
Age (yr) 21.0 ± 2.0 21.0 ± 2.0 
Values are expressed as mean ± SE. WC, White Chocolate; DC, 
Dark Chocolate. 
 
Resting Energy Expenditure (REE).  Pre-supplementation REE (DC 1455 ± 49, WC 1566 
± 49 kcal d-1) were not significantly different between groups (p ≥ .05).  Post 
supplementation REE was significantly increased by 9.5% in DC (Δ REE: DC 138 ± 21, 
WC -30 ± 21 kcal d-1, p = .001) (Fig. 1 and Fig 2).     
 
Fig. 1 – REE before (Pre) and after (Post) dark chocolate (DC) or white chocolate (WC) 
supplementation.  Values are expressed as means ± SE.  # indicates a between groups 




Fig. 2 – Individual subjects REE pre- and post-supplementation with WC (o) or DC ( ). 
 indicates mean data for each group.  # indicates a between groups time effect with the 




Substrate Utilization. There were no significant interaction, time, or group effects for 
resting fat or carbohydrate (CHO) substrate utilization during the assessment of REE 
(Table 2). 
 
 Table 2. Substrate Utilization  
   
WC PRE WC POST DC PRE DC POST 
Fat (g•d-1) 108.7 ± 11.5 100.6 ± 12.1 125.1 ± 11.5 107.2 ± 12.1 
CHO (g•d-1) 128.4 ± 21.7 147.3 ± 30.9   63.7 ± 21.7 138.8 ± 30.9 
Values are expressed as mean ± SE. WC, White Chocolate; DC, Dark Chocolate; PRE, 
before supplementation; POST, after supplementation. There were no significant 
treatment or time effects (p ≥ .05).  
 
 
Exercise Energy Expenditure (EEE).  There were no significant interaction, time, or 
group effects during the assessment of EEE at cycling power outputs of both 50W (EEE-
50) and 100W (EEE-100) (p ≥ .05) (Table 3). 
 
Table 3. Exercise Energy Expenditure (kcal min-1)  
   
WC PRE WC POST DC PRE DC POST 
EEE-50 (kcal•min-1) 
EEE-100 (kcal•min-1) 
4.61 ± 0.15 
6.77 ± 0.16 
4.48 ± 0.16 
6.65 ± 0.17 
4.86 ± 0.15 
7.07 ± 0.16 
4.44 ± 0.16 
6.51 ± 0.17 
Values are expressed as mean ± SE. WC, White Chocolate; DC, Dark Chocolate; PRE, 
before supplementation; POST, after supplementation; EEE at cycling power outputs of 





Oxygen Uptake (VO2). There were no significant interaction, time, or group effects 
during the assessment of VO2 at cycling power outputs of both 50W (VO2-50) and 100W 
(VO2 -100) (p ≥ .05) (Table 4). 
 
Table 4. Absolute VO2 (L min-1)  
   
WC PRE WC POST DC PRE DC POST 
VO2-50 (L min-1) 
VO2-100 (L min-1) 
.939 ± .032 
1.362 ± 0.033 
.910 ± .031 
1.336 ± 0.034 
.990 ± .032 
1.425 ± 0.033 
.907 ± .031 
1.307 ± 0.034 
Values are expressed as mean ± SE. WC, White Chocolate; DC, Dark Chocolate; PRE, 
before supplementation; POST, after supplementation; cycling power output 50W (VO2-
50) and 100W (VO2-100).    
 
 
Respiratory Quotient (RQ).  There were no significant interaction, time, or group effects 
during the assessment of RQ was determined at rest (RQ-0) and at cycling power outputs 
of both 50W (RQ-50) and 100W (RQ-100) (Table 5).  
 
Table 5. Respiratory Quotient  
   
WC PRE WC POST DC PRE DC POST 
RQ-0 .81 ± .02 .82 ± .02 .76 ± .02 .81 ± .02 
RQ-50 
RQ-100 
.91 ± .02 
.97 ± .02 
.92 ± .02 
.97 ± .02 
.91 ± .02 
.96 ± .02 
.93 ± .02 
.97 ± .02 
Values are expressed as mean ± SE. WC, White Chocolate; DC, Dark Chocolate; PRE, 
before supplementation; POST, after supplementation; resting (RQ-0) cycling power 
output 50W (RQ-50) and 100W (RQ-100).    
 
Discussion 
 The purpose of this study was to investigate the influence of a relatively small 
dosage of 70% DC (20 g d-1) of short duration (~30-d) on REE and steady state EEE in a 
group of recreationally fit/athletic females.  The notable findings indicated that DC 
 20 
consumption increased daily REE by ~9.5% (+138 kcal d-1); however, this change was 
not observed in EEE. 
Chocolate has a very rich and storied history, having its beginnings attributed to 
the divine discovery of cacao by the Aztecan god Quetzalcoatl (Feather Serpent).  Blood 
mixed with cacao was deemed as a worthy sacrifice for the gods, and Aztecan human 
sacrifices (prisoners) were fed roasted and ground cacao beans so the gods would find 
their sacrifice most worthy (Dillinger et al., 2000).  Thus, cacao was originally referred to 
as the food of the gods (Coe & Coe, 1996). 
Over the past 500 years, cacao, and its processed form chocolate, have been used 
as a treatment for a plethora of diseases and medical conditions.  These include menstrual 
irregularity, angina, strengthening of the heart, heart palpitations, hypochondria, 
inflammation, insomnia, cancer, conception, hangovers, vaginal irritation, toothaches, 
scurvy, antidote against poison, belching, flatulence, nervousness, and old age.  It was 
also noted that cocoa consumption was sometimes associated with obesity, consequently, 
if someone were underweight, chocolate might provide a tasty option to promote weight 
gain.  (Dillinger et al., 2000)  
The specific mechanisms by which DC impacts physiological function have not 
been clearly elucidated.  Being that nutritional supplements are not closely regulated 
(U.S. Food and Drug Administration, 1994), the recommended dosages are often at the 
discretion of the manufacturer and/or consumer, leading some to the assumption that “if a 
little is good, more is better”.  Thus, a major confounding factor in the interpretation of 
the literature is that there is little consistency in the dosing used in nutritional 
supplementation studies.  A positive health benefit attributed to DC consumption is the 
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strong polyphenol qualities of the flavonoid (-)-epicatechin (Hurst et al., 2011).  
However, there is accumulating evidence suggesting that flavonoids with high total anti-
oxidant capacity (TAC) may actually inhibit, rather than enhance, skeletal muscle 
adaptations to exercise (Hollman et al., 2011; Paulsen et al., 2014).  Thus, it is unlikely 
that the increase in TAC associated with DC supplementation utilized by Taub et al. 
(2016) was responsible for the improvement in maximal oxygen uptake.  It is quite 
plausible that a larger dose of DC may actually exhibit a negative effect on physiological 
function, whereas a smaller dosage would not.  With this thought in consideration, we 
wanted to minimize any potential inhibitory effect of DC associated with an increase in 
TAC and consequently chose to employ a relatively small DC supplementation dosage 
(20 g d-1) and short duration (30 d).   
Whereas, an increase in TAC associated with DC consumption may potentially 
inhibit physiological function, recent evidence suggests a mechanism whereby (-)-
epicatechins may bind to cell surface G protein-coupled estrogen receptors thereby 
positively impacting metabolic control (Moreno-Ulloa et al., 2015).  Taub et. al. (2016) 
recently demonstrated that a 3-month administration of 20g/d-1 of (-)-epicatechin-rich 
cocoa in human adults increased maximal oxygen uptake and cycling power output in a 
group of sedentary, middle-aged males and females.  It was suggested that this positive 
effect might be due to an improvement in mitochondrial efficiency in response to the 
flavonoid, (-)-epicatechin, and indeed this notion was supported by their observed 140% 
increase in citrate synthase activity, a marker of mitochondrial function (Taub et al., 
2016).  Earlier work in isolated mouse muscle indicating that (-)-epicatechin by itself, or 
combined with exercise, also can induce structural and metabolic changes in skeletal and 
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cardiac muscles (Nogueira et al., 2011).  While speculative, our findings of a 9.5% 
increase in REE would suggest significant changes in mitochondrial function likely did 
occur with the administration of a relatively small and brief supplementation of DC. 
Previous studies of both high intensity interval training (Jacobs et al., 2013) and 
aerobic exercise training (Short et. al., 2003) demonstrated 20% and 45% increases in 
skeletal muscle citrate synthase, and an approximate 10% increase in maximal oxygen 
uptake, respectively.  Both of these exercise-induced measures are significantly less than 
that demonstrated in sedentary adults after 3 months of DC supplementation (Taub et. al., 
2016).  In addition, positive markers of oxidative stress were significantly improved with 
DC supplementation (Taub et. al., 2016) in a magnitude quite similar to that observed 
with chronic physical conditioning (Olesen et. al., 2014).  Collectively, these data suggest 
that (-)-epicatechin rich DC may influence bioenergetics in a magnitude similar to, or 
possibly even greater than, that observed with physical conditioning. 
As indicated previously, (-)-epicatechin alone, and in combination with exercise, 
promotes structural and metabolic changes in mouse skeletal and cardiac muscles and 
endurance capacity (Nogueira et al., 2011).  In contrast, Copp et al. (2013) reported that 
(-)-epicatechin administration had no impact on resting oxygen uptake or exercise 
performance.  While any explanation for the contrary findings is just speculative, two 
thoughts come to mind: 1) Is there a species difference (mice vs. rats) in the response to 
(-)-epicatechin administration?  2) Was the difference in (-)-epicatechin dosage 
responsible for the different findings?  The positive findings of Nogueira et al. (2011) 
were in response to an (-)-epicatechin administration of 2 mg kg-1 d-1 for 15 d, whereas 
the absence of positive findings reported by Copp et al. (2013) were in response to an (-)-
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epicatechin administration of 4 mg kg-1 d-1 for 24 d.  Considering the accumulating 
evidence suggesting that a high TAC may actually inhibit skeletal muscle adaptations 
(Hollman et al., 2011; Paulsen et al., 2014), the conflicting exercise performance findings 
are not surprising. 
 With regards to steady state EEE, we had conditionally hypothesized that if 
changes in REE were observed in response to DC supplementation, similar changes 
would be observed during steady state EEE.  Surprisingly, this was not the case.  While 
Taub et al. (2016) employed a similar DC dosage for 90 d and reported a 17% increase in 
maximal oxygen uptake and improved cycling endurance to exhaustion, our protocol 
supplementation duration was only 30 d and evaluated the metabolic response during 
steady state exercise, not maximal exercise performance.  In addition, the subjects 
assessed in our study were relatively young (~21 years), recreationally fit/competitive 
females, whereas the subjects of Taub et al. (2013) were middle aged (~49 years) and 
sedentary.  Due to the difference between the exercise protocols, as well as the difference 
between subject characteristics, our findings are not surprising.   
 In summary, to our knowledge this is the first study to demonstrate that a 
relatively small daily dosage of DC can significantly elevate REE but does not impact 
steady state EEE.  Future DC supplementation studies are warranted investigating: 1) 
energy balance, weight control, and body composition, 2) energy metabolism in 
sedentary vs. exercise trained males and females, 3) energy metabolism of post-
menopausal and aged females, and 4) exercise metabolism and skeletal muscle 




Allgrove, J., Farrell, E., Gleeson, M., Williamson, G., & Cooper, K. (2011). Regular 
Dark Chocolate Consumption’s Reduction of Oxidative Stress and Increase of 
Free-Fatty-Acid Mobilization in Response to Prolonged Cycling. International 
Journal of Sport Nutrition and Exercise Metabolism, 21(2), 113-123.  
Beg, M. S., Ahmad, S., Jan, K., & Bashir, K. (2017). Status, supply chain and processing 
of cocoa - A review. Trends in Food Science & Technology, 66, 108-116.  
Coe, S. D. & Coe, M. D. (1996).  The True History of Chocolate. London, U.K.: Thames 
& Hudson. 
Copp, S.W., Inagaki, T., White, M. J., Hirai, D. M., Ferguson, S. K., Holdsworth, C. 
T., Sims, G. E., Poole, D. C., Musch, T. I. (2013). (-)-Epicatechin administration 
and exercising skeletal muscle vascular control and microvascular oxygenation in 
healthy rats. Am J Physiol Heart Circ Physiol. 304(2): H206-14. 
Davis, J. M., Carlstedt, C. J., Chen, S., Carmichael, M. D., & Murphy, E. A. (2010). The 
Dietary Flavonoid Quercetin Increases VO2maxand Endurance Capacity. 
International Journal of Sport Nutrition and Exercise Metabolism, 20(1), 56-62.  
Davison, G., Callister, R., Williamson, G., Cooper, K. A., & Gleeson, M. (2011). The 
effect of acute pre-exercise dark chocolate consumption on plasma antioxidant 
status, oxidative stress and immunoendocrine responses to prolonged exercise. 
European Journal of Nutrition, 51(1), 69-79.  
Decroix, L., Tonoli, C., Soares, D. D., Descat, A., Drittij-Reijnders, M., Weseler, A. R., . 
. . Meeusen, R. (2017). Acute cocoa Flavanols intake has minimal effects on 
exercise-induced oxidative stress and nitric oxide production in healthy cyclists: 
 25 
A randomized controlled trial. Journal of the International Society of Sports 
Nutrition, 14(1).  
Dillinger, T. L., Barriga, P., Escarcega, S., Jimenez, M., Lowe, D. S., & Grivetti, L. E. 
(2000). Chocolate: Modern Science Investigates an Ancient Medicine. Journal of 
Nutrition, 130, 2057-2072.  
Fattore, E., & Fanelli, R. (2013). Palm oil and palmitic acid: A review on cardiovascular 
effects and carcinogenicity. International Journal of Food Sciences and Nutrition, 
64(5), 648-659.  
Grassi, D., Lippi, C., Necozione, S., Desideri, G., & Ferri, C. (2005). Short-term 
administration of dark chocolate is followed by a significant increase in insulin 
sensitivity and a decrease in blood pressure in healthy persons. The American 
Journal of Clinical Nutrition, 81, 611-614.  
Gutierrez-Salmean, G., Ciaraldi, T. P., Nogueira, L., Barboza, J., Taub, P. R., Hogan, M. 
C., . . . Ramirez-Sanchez, I. (2014). Effects of (−)-epicatechin on molecular 
modulators of skeletal muscle growth and differentiation. The Journal of 
Nutritional Biochemistry, 25(1), 91-94.  
Hamed, M. S., Gambert, S., Bliden, K. P., Bailon, O., Anand, S., Antonino, M. J., . . . 
Gurbel, P. A. (2008). Dark Chocolate Effect on Platelet Activity, C-Reactive 
Protein and Lipid Profile: A Pilot Study. Southern Medical Journal, 101(12), 
1203-1208.  
Hernández, F. (1577/1942).  Historia de las Plantas de la Nueva España.  Imprenta 
Universitaria, México City, Mexico. 
 26 
Hollman, P. C., Cassidy, A., Comte, B., Heinonen, M., Richelle, M., Richling, 
E., Serafini, M., Scalbert, A., Sies, H., Vidry, S. (2011). The biological relevance 
of direct antioxidant effects of polyphenols for cardiovascular health in humans is 
not established. J Nutr, 1(5): 989S-1009S 
Hurst, W. J., Krake, S. H., Bergmeier, S. C., Payne, M. J., Miller, K. B., & Stuart, D. A. 
(2011). Impact of fermentation, drying, roasting and Dutch processing on flavan-
3-ol stereochemistry in cacao beans and cocoa ingredients. Chemistry Central 
Journal, 5(1), 53.  
Jacobs R. A., Flück, D., Bonne, T.C., Bürgi S., Christensen, P.M., Toigo, M., Lundby, C. 
(2013). Improvements in exercise performance with high-intensity interval 
training coincide with an increase in skeletal muscle mitochondrial content and 
function.  J Appl Physiol, 115(6), 785-93. 
Latif, R. (2013). Chocolate/cocoa and human health: a review. The Journal of Medicine, 
71(2), 63-68.  
Lippi, G., Franchini, M., Montagnana, M., Favaloro, E. J., Guidi, G. C., & Targher, G. 
(2008). Dark chocolate: consumption for pleasure or therapy? Journal of 
Thrombosis and Thrombolysis, 28(4), 482-488.  
Lyall, K. A., Hurst, S. M., Cooney, J., Jensen, D., Lo, K., Hurst, R. D., & Stevenson, L. 
M. (2009). Short-term blackcurrant extract consumption modulates exercise-
induced oxidative stress and lipopolysaccharide-stimulated inflammatory 
responses. American Journal of Physiology-Regulatory, Integrative and 
Comparative Physiology, 297(1), 70-81.  
 27 
Moreno-Ulloa, A., Mendez-Luna, D., Beltran-Partida, E., Castillo, C., Guevara, G., 
Ramirez-Sanchez, I., Correa-Basurto, J., Cabello, G., Villarreal, F. (2015). The 
effects of (-)-epicatechin on endothelial cells involve the G protein-coupled 
estrogen receptor (GPER). Pharmacol Res., 100:309-20. 
Morillas-Ruiz, J., García, J. V., López, F., Vidal-Guevara, M., & Zafrilla, P. (2006). 
Effects of polyphenolic antioxidants on exercise-induced oxidative stress. Clinical 
Nutrition, 25(3), 444-453.  
Morillas-Ruiz, J., Zafrilla, P., Almar, M., Cuevas, M. J., López, F. J., Abellán, P., . . . 
González-Gallego, J. (2005). The effects of an antioxidant-supplemented 
beverage on exercise-induced oxidative stress: results from a placebo-controlled 
double-blind study in cyclists. European Journal of Applied Physiology, 95(5-6), 
543-549.  
Mursu, J., Voutilainen, S., Nurmi, T., Rissanen, T. H., Virtanen, J. K., Kaikkonen, J., . . . 
Salonen, J. T. (2004). Dark Chocolate Consumption Increases HDL Cholesterol 
Concentration and Chocolate Fatty Acids May Inhibit Lipid Peroxidation in 
Healthy Humans. Free Radical Biology and Medicine, 37(9), 1351-1359.  
Nogueira, L., Ramirez-Sanchez, I., Perkins, G. A., Murphy, A., Taub, P. R., Ceballos, G., 
. . . Malek, M. H. (2011). (–)-Epicatechin enhances fatigue resistance and 
oxidative capacity in mouse muscle. The Journal of Physiology, 18(589), 4615-
4631. doi:10.1113/jphysiol.2011.209924 
Olesen, J., Gliemann, L., Biensø, R., Schmidt, J., Hellsten, Y., Pilegaard, H. 
(2014) Exercise training, but not resveratrol, improves metabolic and 
inflammatory status in skeletal muscle of aged men. J Physiol, 592(8):1873-86.  
 28 
Paulsen, G., Cumming, K. T., Holden, G., Hallén, J., Rønnestad, B. R., Sveen, O., Skaug, 
A., Paur, I., Bastani, N. E., Østgaard, H. N., Buer, C., Midttun, M., Freuchen, 
F., Wiig, H., Ulseth, E. T., Garthe, I., Blomhoff, R., Benestad, H. B., Raastad, T. 
(2014). Vitamin C and E supplementation hampers cellular adaptation to 
endurance training in humans: a double-blind, randomized, controlled trial. J 
Physiol, 592(8):1887-901. 
Peake, J. M., Suzuki, K., & Coombes, J. S. (2007). The influence of antioxidant 
supplementation on markers of inflammation and the relationship to oxidative 
stress after exercise. The Journal of Nutritional Biochemistry, 18(6), 357-371.  
Petyaev, I. M., & Bashmakov, Y. K. (2017). Dark Chocolate: Opportunity for an Alliance 
between Medical Science and the Food Industry? Frontiers in Nutrition, 4, 1-8.  
Powers, S. K., Quindry, K. C., J., & Hamilton, K. L. (2004). Dietary antioxidants and 
exercise. Journal of Sports Sciences, (22), 81-94.  
Rodriguez-Mateos, A., Hezel, M., Aydin, H., Kelm, M., Lundberg, J. O., Weitzberg, E., . 
. . Heiss, C. (2015). Interactions between cocoa flavanols and inorganic nitrate: 
Additive effects on endothelial function at achievable dietary amounts. Free 
Radical Biology and Medicine, 80, 121-128.  
Roura E., Andrés-Lacueva, C., Estruch, R., Mata-Bilbao, M.L., Izquierdo-Pulido, 
M., Waterhouse, A.L., Lamuela-Raventós, R.M. (2007). Milk does not affect the 
bioavailability of cocoa powder flavonoid in healthy human. Ann Nutr 
Metab. 51(6), 493-498. 
 Short, K. R., Vittone, J. L, Bigelow, M. L, Proctor, D. N., Rizza, R. A., Coenen-
Schimke, J.  M,, Nair, K. S. (2003). Impact of aerobic exercise training on age-
 29 
related changes in insulin sensitivity and muscle oxidative capacity. Diabetes, 
52(8):1888-96. 
Solomon, S. J., Kurzer, M. S., & Calloway, D. H. (1982). Menstrual cycle and basal 
metabolic rate in women. The American Journal of Clinical Nutrition, 36(4), 611-
616.  
Taub, P. R., Ramirez-Sanchez, I., Patel, M., Higginbotham, E., Moreno-Ulloa, A., 
Román-Pintos, L. M., . . . Villarreal, F. (2016). Beneficial effects of dark 
chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A 
double blind, randomized, placebo-controlled trial. Food & Function, 7(9), 3686-
3693.  
Tokede, O. A., Gaziano, J. M., & Djoussé, L. (2011). Effects of cocoa products/dark 
chocolate on serum lipids: A meta-analysis. European Journal of Clinical 
Nutrition, 65(8), 879-886. 
U.S. Food and Drug Administration (1994). Dietary Supplement Health and Education 
Act of 1994. Retrieved from https://www.fda.gov/Food/DietarySupplements/ 
default.htm  
Varela, C. E., Rodriguez, A., Romero-Valdovinos, M., Mendoza-Lorenzo, P., Mansour, 
C., Ceballos, G., . . . Ramirez-Sanchez, I. (2017). Browning effects of (-)-
epicatechin on adipocytes and white adipose tissue. European Journal of 
Pharmacology, 811, 48-59. 
Venables, M. C., Hulston, C. J., Cox, H. R., & Jeukendrup, A. E. (2008). Green tea 
extract ingestion, fat oxidation, and glucose tolerance in healthy humans. The 
American Journal of Clinical Nutrition, 87(3), 778-784. 
 30 
Verna, R. (2013). The history of chocolate. Science of Chocolate, 35(2), 111-121.  
Vlachopoulos, C., Aznaouridis, K., Alexopoulos, N., Economou, E., Andreadou, I., & 
Stefanadis, C. (2005). Effect of Dark Chocolate on Arterial Function in Healthy 
Individuals. American Journal of Hypertension, 18(6), 785-791.  
Weir, J. B. (1949). New methods for calculating metabolic rate with special reference to 










































Valdosta State University 
 APPLICATION FOR USE OF HUMAN PARTICIPANTS IN RESEARCH
  
EXPEDITED APPLICATION 
INSTRUCTIONS: Complete this form by checking all appropriate boxes.  Attach all CITI training 
documents, and obtain all necessary signatures before submitting to the Office of Sponsored Programs & 
Research Administration. 
 
Project Title: Chocolate Consumption: Effect on Resting and Exercise Metabolism    Project Dates:   Jan 2018 to 
Dec 2018 
                         
MM/DD/YYYY       MM/DD/YY 
Responsible Researcher: Katie Presler Minimum # of Participants: 40                                  
Mailing Address:    HSBA building office 2137                                       Maximum # of Participants: 50 
Department: Health Science Exercise Physiology                                                       External Funding:    Yes        
   No  
E-mail: KPresler@Valdosta.edu If Yes, Sponsor:   
Telephone: 951-533-3693                                                  
 
Supervising Faculty: Michael Webster 
Supervising Faculty Email: MJWebster@Valdosta.edu 









Graduate Student  
 Doctoral 
Dissertation 
 Master’s Thesis 
Undergraduate Student 
 Senior Project 
 
Unaffiliated Investigator 
 *Note: Unaffiliated Investigators must fill out the last column “IRB FWA#” and complete an unaffiliated agreement 
form found at:  http://www.valdosta.edu/academics/graduate-school/research/office-of-sponsored-programs-research-administration/institutional-review-board-
irb-for-the-protection-of-human-research-participants.php 
1.  YES    NO Does your proposed study (a) meet the Valdosta State University Institutional 
Review Board definition of research (as cited below) or (b) does it involve a 
condition for IRB oversight as listed below? 
 VSU IRB Definition of Research:  Valdosta State University describes research as a systematic investigation, 
including research development, testing and evaluation designed to develop or contribute to generalizable knowledge.  
 
Conditions: The following conditions may not meet the definition of “research” as provided above, but will cause your 
research to be subject to IRB oversight:  
 Intent to produce results that will be submitted for peer-reviewed publication or presentation 
 Include minors (e.g. those under the age of 18) 
 Target potentially vulnerable individuals 
 May place pregnant women and/or fetuses at risk of physical harm 
 Deal with a topic of sensitive nature in a way which anonymity cannot be sustained 
Co-investigator Institutional 
Affiliation   
Email Address         *IRB FWA # 
    
    
    
    
    
    
    
    
(Note: If the research is or will be externally funded, include a copy of the 
portion of the proposal or award that describes use of human participants.) 
 33 
 Involve any activity that places the participants at more than minimal risk (see Question 9 for 
definition of “minimal risk”) 
  
2.  YES    NO        Are the human participants in your study living individuals or are you collecting 
information about deceased persons that may put third parties (i.e., surviving 
spouses and/or living descendants) at more than minimal risk of harm? 
 
3.  YES    NO    Will you obtain data through intervention or interaction with living or third-party 
individuals? 
         “Intervention” includes both physical procedures by which data are gathered (e.g. measurement of heart 
rate of venipuncture)  
        “Interaction” includes communication or interpersonal contact between the investigator and participant 
(e.g. surveying or interviewing) 
 
4.  YES    NO    Will you obtain identifiable private information about these individuals? 
         Private information includes information about behavior that occurs in a context in which an individual 
can reasonably expect that no      
       observation or recording is taking place. Identifiable means that the identity of the participant maybe 
ascertained by the investigator. 
 
(1) Does your work involve human blood, body fluids, cells, or tissue components? 
 
(2) Does your work involve recombinant DNA or a biohazardous agent?  
 
Note: If you answered NO to Question 1 or 2, no IRB review is required. If you answered NO to Question 3 AND 4, no IRB review is 
required. If you have any questions on whether you are conducting research that needs IRB oversight please review the IRB Exempt 
Flowchart on our website.  
 
5. EDUCATIONAL REQUIREMENTS: In accordance with federal regulations, the VSU IRB requires all responsible 
researchers, co-investigators, key personnel, including unaffiliated investigators, and faculty advising student researchers to 
complete the CITI educational program. Co-investigators from other institutions are not required to complete this if they have a 
certificate of completion from their own federally assured IRB. 
Please visit: http://ww.citiprogram.org to complete all of the following mandatory trainings: 
1. Introduction 
2. History and Ethical Principles 
3. Defining Research with Human Subjects 
4. The Regulations and the Social and Behavioral sciences 
5. Basic Institutional Review Board (IRB) Regulations and Review Process 
6. Assessing Risk in Social and Behavioral Sciences 
7. Informed Consent  
8. Privacy and Confidentiality 
9. Valdosta State University Module 
 
Additional modules may be required for specific types of research. Please check all that apply and complete the 
corresponding modules: 
Study population targets Additional CITI Modules Required 
 a. Minors (under the age of 18) Research with Children 
 b. Public school Children Research in Public Elementary and Secondary Schools 
 c. Pregnant Women  Vulnerable Subjects 
 d. Prisoners Research with Prisoners 
 e. Potentially vulnerable individuals (those whose 
consent maybe compromised due to socio-economic, 
educational or linguistic disadvantage.) 
Research with Protected Populations 
 f. Individuals in foreign countries International Research 
 g. Individuals from different cultures or individuals from 
a particular racial/ethnic group 
Group Harms: Research with Culturally or Medically 
Vulnerable groups 
 h. Individuals about whom data will be collected from 
records (e.g., educational, health, or employment records) 
Records-Based Research 
 i. Individuals from or about whom Private Health 
Information (PHI) subject to HIPAA compliance will be 
collected 
HIPAA and Human Subjects 
 j. Individuals from whom information will be collected 
via Internet 
Internet Research 





6.  YES    NO    Does the primary researcher, co-investigator, or any other key person, have a 
potential or actual significant financial conflict of interest in performance of 
the research? 
    
If YES, please complete the CITI module “Conflicts on Interest in Research Involving Human Subjects” 
AND  
complete the VSU Conflict of Interest form available at http://www.valdosta.edu/grants/forms. 
7.  As a researcher you are expected to follow VSU’s code of ethics. Will there be an additional code 
of ethics followed? 
 Include organization’s name & Web address: 
    NO 
8. Name and location of external organization(s) providing research participants (attach letter(s) of 
cooperation): 
        
 
9.  YES    NO     UNCERTAIN Does the study present more than minimal risk to the 
participants?     
“Minimal Risk” means that the risks of harm or discomfort anticipated 
in the proposed research are not greater, considering probability and 
magnitude, than those ordinarily encountered in daily life or during 
performance of routine physical or psychological examinations or 
tests. Note that the concept of risk includes psychological, emotional, 
or behavioral risks to employability, economic well-being, social 
standing, and risk of civil criminal liability. 
  
10. If the research project can be described by one or more of the categories listed below, please check 
all that apply: 
 
 Category 1 - Clinical studies of drugs and medical devices only when  
(a) the research is on drugs for which an investigational new drug application (21 CFR 312) is not 
required or  
(b) the research is on medical devices for which  
(i)  an investigational device exemption application (21 CFR 812) is not required or  
(ii) the medical device is cleared/approved for marketing and the medical device is being 
used in accordance with its cleared/approved labeling.  
 
 Category 2 - Collection of blood samples by finger stick, heal stick, ear stick, or venipuncture from  
(a) healthy, non-pregnant adults who weigh at least 110 pounds for whom  
(i) the amounts drawn do not exceed 550 ml in an 8-week period and  
(ii) collection does not occur more frequently than 2 times per week or  
(b) other adults and children, for whom, considering the age, weight, and health of the participants, 
and the collection procedures,  
(i) the amount of blood to be collected does not exceed the lesser of 50 ml or 3 ml per kg 
in an 8-week period and  
(ii) collection does not occur more frequently than 2 times per week.  
(NOTE: Children are defined as "persons who have not attained the legal age for consent to treatments or procedures 
involved in the research, under the applicable law of the jurisdiction in which the research will be conducted.") 
  
 Category 3 - Prospective collection of biological specimens for research purposes by noninvasive 
means, including: 
(a) hair and nail clippings, in a non-disfiguring manner;  
(b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction;  
(c) permanent teeth if routine patient care indicates a need for extraction;  
(d) excreta and external secretions (including sweat);  
(e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum 
base or wax or by applying a dilute citric solution to the tongue;  
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(f) placenta removed at delivery;  
(g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;  
(h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not 
more invasive than routine prophylactic scaling of the teeth and the process is accomplished in 
accordance with accepted prophylactic techniques;  
(i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; 
and  
(j) sputum collected after saline mist nebulization.  
 
 Category 4 - Collection of data through non-invasive procedures (not involving general anesthesia or 
sedation) routinely employed in clinical practice, excluding procedures involving x-rays 
or microwaves. Such procedures include: 
(a) physical sensors that are applied either to the surface of the body or at a distance and do not 
involve input of significant amounts of energy into the participant or an invasion of the 
participant's privacy;  
(b) weighing or testing sensory acuity;  
(c) magnetic resonance imaging;  
(d) electrocardiography, electroencephalography, thermography, detection of naturally occurring 
radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow, 
and echocardiography; and  
(e) moderate exercise, muscular strength testing, body composition assessment, and 
flexibility testing where appropriate given the age, weight, and health of the individual.  
(NOTE: Where medical devices are employed, they must be cleared/approved for marketing.)  
 Category 5 -  Research involving materials (data, documents, records, or specimens) that have been 
collected, or will be collected, solely for non-research purposes (such as medical treatment 
or diagnosis).  
 Category 6 - Collection of data from voice, video, digital, or image recordings made for research 
purposes.  
 
 Category 7 - Research on individual or group characteristics or behavior (including, but not limited to, 
research on perception, cognition, motivation, identity, language, communication, cultural 
beliefs or practices, and social behavior) or research employing survey, interview, oral 
history, focus group, program evaluation, human factors evaluation, or quality assurance 
methodologies.  
 
11. Selection of Participants and Voluntariness:  
a) Participant Population: 
40-50 females will be recruited for participation in the study. Half (N = 20-25) of these 
individuals will be 18-30 years of age whereas the other half (N = 20-25) will be post-
menopausal 50-70 years of age. Inclusion in the study requires that they have a body mass index 
(BMI) (weight in kg / height in meters2) of greater than 18.5 or less than 30.0, be non-smokers, 
not regularly (2-3 times per week) consuming chocolate and not presently taking any nutritional 
supplements that might possibly alter metabolic rate.  They must also indicate that they are free of 
any physical condition(s) that would prevent them from completing the physical demands of 
participation, or put them at more than the expected physical risk, when performing the required 
exercise.  Individuals that are knowingly pregnant, think they might be pregnant, or actively 
trying to conceive, will be excluded from participation in the study.  All participants will be 
required to complete a physical activity and pre-participation health history questionnaire to 
screen-out any individuals that present exclusionary criteria. 
 
Inclusion: 
 18-30 years of age (N = 20-25)  
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 BMI of 18.5 - 30.0 
 Free of any physical condition(s) that would prevent them from completing the physical 
demands of participation, or put them at more than the expected physical risk, when 




 Not 18-30 years of age  
 BMI of < 18.5 or > 30.0 
 Presently taking, or have taken in the past 30 days, any nutritional supplement or 
medication that might possibly alter metabolic rate 
 Individuals that are knowingly pregnant, think they might be pregnant, or actively trying 
to conceive 
 Presenting a pre-participation health history questionnaire indicating any health 
conditions, or any potential medication/supplement interactions that would warrant 
exclusion from participation.  All responses to the questionnaire will be evaluated by a 
qualified, licensed medical professional and final approval for participation will be 
provided by this individual.  If exclusion is warranted, the subject will be informed via 
an in-person meeting with the investigator. 
 Smoker 
 Regular consumer of dark chocolate 
 
b) Methods for Selecting Participants: 
 E-mail blast to the VSU faculty and student population 
 Fliers will be posted on bulletin boards around the HSBA building and in the VSU 
Recreation Center (see appendix 9) 
 Word-of-mouth 
 Any individual that meets the requirements for participation is welcome 
 
c) Assurance that Participation is Voluntary: 
 Participation in the study is 100% voluntary 
 All participants are free to withdraw from the study at any time without penalty 
 For students, there are no academic incentives (e.g., extra credit) for participation and 
likewise there are no academic penalties for not participating  
 
12. Informed Consent 
(See Appendix – 1) 
 
13. Compensation: 
 Participation is completely voluntary and there are no costs to the participant 
 Upon completion of the project subjects will be provided with information about their: 
o Body composition 
o Resting energy expenditure  
o Exercise energy expenditure 
 If requested, subjects will also be provided with any presentation abstracts, publication 
abstracts, or manuscripts resulting from their participation 
 
14. Deception:  
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The research protocol is a randomized, matched-pairs, double-blind design; however, there is no 
deception involved. 
  
15. Research Protocol: 
There are two groups of subjects for this study, each of which will be randomly assigned 
to one of two experimental conditions: 
 
 18- to 30-year-old females.  N = 20-25 
o Experimental condition A = Dark chocolate – 20 grams of dark chocolate 
powder per day for 30-days 
o Experimental condition B = White Chocolate – 20 grams of a white chocolate 
placebo per day for 30-days 
 
Both the dark chocolate and white chocolate are provided by the Hershey.  White chocolate is 
serving as the placebo due to the fact that it does not contain any (-)-epicatechin, which is the 
active component of dark chocolate that is being evaluated in this study.  Subjects will not be 
aware that the specific intent of the study is to investigate dark chocolate. 
 
Laboratory Visit #1 (~90-minutes): 
Laboratory Visit #1 will require the subject to read the informed consent and then they will also 
have the opportunity to ask any questions related to their participation in the study.  At this visit 
they will also complete a physical activity and health history questionnaire (see appendix 3).  
Initial resting measurements of body weight, height, heart-rate, and blood pressure will be 
obtained.  Body composition (body fat and lean tissue) will be determined via DEXA (see 
appendix 7).   
 
A preliminary/familiarization 20-minute submaximal cycling exercise test will be performed on a 
laboratory cycle (see appendix 6). This test will require the subject to be fitted with a heart rate 
monitor chest strap (see appendix 8) and also a facemask that covers both the nose and mouth 
(see appendix 5). This facemask will allow the subject to breathe freely so that during the 
exercise test breathing rate, air volume, and expired concentrations of oxygen and carbon 
dioxide can be determined.  Once the heart rate monitor and facemask are in place, the subject 
will perform a 20-minute bout of exercise on the cycle.  The first 10 minutes will be performed 
at a relatively low workload and the second 10 minutes will be performed at a moderate 
workload.  
o 10 minutes cycling at 50 watts  
o 10 minutes of cycling at 100 watts  
 
Upon completion of the 20-minutes of cycling, subjects will be given a 3-minute recovery before 
commencing with a maximal exercise performance test as follows: 
 Exercise Performance Test 
o 1 km cycling time-trial.  The goal is to complete the 1 km as quickly as possible 
(~2-3 minutes) 
 
Summary of the Laboratory Visit #1 (~90 minutes): 
 Participation documents 
 38 
 Informed Consent 
 Physical activity and health history questionnaires 
 Resting Measurements 
 body weight 
 height 
 heart-rate 
 blood pressure 
 body composition via DEXA 
Cycling Exercise Test 
 20 minutes test on the cycle 
Exercise Performance Test 
o 1 km cycling time-trial 
Assignment of date for next visit 
 Schedule a day and time for their return to the laboratory within the following week.  
 
Laboratory Visit #2 (~60-90 minutes):  
During this visit the subject will be required to arrive in the laboratory in an 8-hour fasted state 
(no food or drink other than water).  Additionally, they must not have consumed any caffeine or 
alcohol, nor performed more than 20 minutes of low intensity exercise during the previous 24-
hours.   
 
Upon arrival to the laboratory, the subject will be requested to void their bladder and then their 
resting energy expenditure (REE) will be determined by analysis of the gases expired by them 
while resting in a supine position (Vyasis Vmax Encore) on an examination table. This process 
requires the subject to remain relatively motionless, yet remain awake, on an exam table for 
approximately 30-min.  To obtain the metabolic measurements, a transparent canopy will be 
placed over the subject’s neck and head and this is connected by a tube to an expired air mixing 
chamber for the analysis of expired gases (oxygen and carbon dioxide) (see appendix 4). 
 
After completion of the test for REE, a 20-minute submaximal cycling exercise test will be 
performed in the same manner indicated previously, with the first 10 minutes performed at a 
relatively low workload and the second 10 minutes performed at a moderate workload.  Upon 
completion of the 20-minutes of cycling, subjects will be given a 3-minute recovery before 
commencing with an exercise performance test, again, in the same fashion described previously. 
 
After completion of the exercise performance test, subjects will be provided with either the dark 
chocolate or the placebo - white chocolate using a randomized, double-blind, matched pairs 
research design.  Before departing the laboratory, the day and time for the subject’s next visit to 
the laboratory in 30-days will be scheduled. 
 
Summary of Laboratory Visit #2 (~60-90 min): 
 Resting Measurements 
 Resting Energy Expenditure 
Cycling Exercise Test 
 20-minutes test on the cycle 
Exercise Performance Test 
o 1 km cycling time-trial 
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 Assignment of experimental supplement (randomized, double-blind, matched pairs 
research design) 
o Dark chocolate 
o White chocolate - Placebo 
Assignment of date for next visit 
 Schedule a day and time for their return to the laboratory in 30-days.  
  
Laboratory Visit #3 (~60-90 minutes):  
During this visit, the subject will replicate all testing as performed in laboratory visit #2.   
 
Summary of Laboratory Visit #3 (~60-90 min): 
 Resting Measurements 
 Resting Energy Expenditure 
Cycling Exercise Test 
 20-minute test on the cycle 
Exercise Performance Test 
 1 km cycling time-trial 
 
Data collector’s qualifications and Training 
Primary Investigator – Masters’ graduate student, Katie Presler, is trained in all aspects of this 
study.  She is experienced with the use and programming of the laboratory cycle, the calibration 
and use of metabolic measurement system for the assessment of resting and exercise energy 
expenditure, the calibration and use of the DEXA for the assessment of body composition, and 
she is adult CPR/First Aid certified.  She has completed CITI training for “Conflicts of Interest” 
and “Human Research – IRB” (see appendix 2). 
 
Major Professor/Co Investigator - Dr. Michael Webster, Associate Professor of Exercise 
Physiology, has been conducting human performance laboratory exercise studies in higher 
education for 30 years.  He has completed CITI training for “Conflicts of Interest” and “Human 
Research – IRB” (see appendix 2). He has American Red Cross Adult/Infant CPR and AED 
certification and has also been certified with the American College of Sports Medicine as a 
Clinical Exercise Physiologist since 1988.  Part of this certification is the demonstration of 
appropriately responding to medical emergencies.  
 
Arrangements for referral of participants to support services or assistance that may be 
needed as a result of their participation in the research  
If a subject is injured as a result of their participation in this study, they are instructed to contact 
Dr. Michael Webster at 601-543-8926 (cell) or 229-333-7191 (office).  They are also informed 
that neither the researcher nor Valdosta State University has made special provision for services 
required to treat any injury/psychological distress that may result from participation in this 
research study beyond those normally provided to VSU students.  VSU student participants will 
be informed that they may request health care services from Student Health Services at 229-333-
5886 or from their own private health care provider under their selected health insurance plan.  
By agreeing to participate in this research project, subjects are informed that they are not waiving 
any rights that they may have against Valdosta State University for injury resulting from 
negligence of the University or its researchers. 
  
16. Privacy and Confidentiality:  
 40 
Upon agreement to participate in the study, each subject will be assigned a letter/number 
identification known only by the researchers and kept in a file secured in the PI office.  Individual 
data collected in the course of the study will only be divulged upon completion of the study to the 
individual participant from which the data are collected.  Only group data will be reported for 
presentation and publication purposes.  In the event of a medical emergency an individual’s data 
will be provided to their physician upon request by the physician and/or the subject.  This will 
necessitate exclusion from further participation in the study.  All data collected during the course 
of the study will be kept in a file secured in the PI office and/or computer.  All data will be 
retained for a period of 3 years after completion of the study and then all paper data shredded and 
electronic data deleted.  
 
17. Risks: 
Risk of participation is minimal; however, no risk can be completely eliminated. The following 
are aspects of risk associated with participation: 
 
 Exercise - Exercise of any kind puts an individual at an elevated, yet still rare, risk of 
dizziness, fainting, nausea, vomiting, acute myocardial infarction (heart attack), stroke, 
and/or sudden death.  While there is a risk, the likelihood of any of these events occurring 
is minimal due to the fact that you have no known personal health risk history, and/or 
signs and symptoms of cardiovascular disease. 
 
 Supplementation – Commercially available dark chocolate is being assessed in this 
study.  There are no reported side-effects/adverse events associated with the consumption 
of dark chocolate in the quantity (20 grams = <2/3 of an ounce) consumed in this study. 
   
 DEXA (dual energy x-ray absorptiometry) - is a commonly used procedure to assess 
an individual’s body composition (percentage fat and lean tissue) as well as bone density.  
This requires the participant to lay in a supine position (on their back) with their arms at 
their sides for 5-minutes while a very low dose x-ray (0.04 - 0.08 mrem) is passed across 
the body to determine the density of their tissues (fat, lean, bone).  While there is X-ray 
exposure, this is very minimal, as a 5-minute scan provides approximately the same x-ray 
exposure as 2 hours under normal room lighting.  There have been no reported side-
effects/adverse events associated with multiple DEXA measurements.    
 
18. Benefits:  
Subjects will not benefit academically from participation in this research project. 
 
 Upon completion of the project subjects will be provided with information about their:  
o body composition 
o resting energy expenditure  
o exercise energy expenditure 
o exercise performance 
o If requested, subjects will also be provided with any presentation abstracts, 
publication abstracts, or manuscripts resulting from their participation 
  
19. Prior Research: 
Katie Presler – Primary Investigator, is the PI for this study and is trained in all aspects of this 
study.  She is experienced with the use and programming of the laboratory cycle, the calibration 
and use of metabolic measurement system for the assessment of resting and exercise energy 
expenditure, and she is adult CPR/First Aid certified.  She has completed CITI training for 
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“Conflicts of Interest” and “Human Research – IRB” (see appendix 2). 
 
Dr. Michael Webster, Associate Professor of Exercise Physiology, is the supervising faculty of 
this project.  He has been conducting human performance laboratory exercise studies in higher 
education for >30 years.  He has completed CITI training for “Conflicts of Interest” and “Human 
Research – IRB” (see appendix 2). He has American Red Cross Adult/Infant CPR and AED 
certification and has also been certified with the American College of Sports Medicine as a 
Clinical Exercise Physiologist since 1988.  Part of this certification is the demonstration of 
appropriately responding to medical emergencies.    
 
CERTIFICATIONS AND REQUIRED SIGNATURES  
(Note: Please print this page to sign. Applications without all required signatures will be not be 
reviewed.)  
Statement of Responsible Researcher:  
 
I certify that I have completed required training regarding human participant research ethics 
and am familiar with the ethical guidelines and regulations regarding the protection of human 
participants from research risks. I will adhere to the policies and procedures of the Valdosta 
State University Institutional Review Board (IRB). I will not initiate this research project until I 
receive written exemption or approval from the IRB. I will not involve any participant in the 
research until I have obtained and documented his/her informed consent as required by the 
IRB. I agree to (a) report to the IRB any unanticipated problems or adverse events which 
become apparent during the course or as a result of the research and the actions taken as a 
result, (b) cooperate with the IRB in the continuing review of this project; (c) obtain prior 
approval from the IRB before amending or altering the scope of the project or the research 
protocol, and (d) maintain documentation of consent and research data and reports for a 
minimum of three years and in accordance with approved data retention and procedures and 
confidentiality requirements after completion of the final report or longer if required by the 
sponsor or the institution. I understand that my department chair/unit director/faculty 
advisor (if I am a student) will receive a copy of my IRB exemption or approval report.  
 
 
SIGNATURE: Katie Presler /           
Date: 12/7/2017  
                       Responsible Researcher  
 
 
Statement of Supervising Faculty if Responsible Researcher is a Student:  
 
I certify that I am familiar with the ethical guidelines and regulations regarding the protection 
of human participants from research risks and have completed training required by the VSU 
IRB. I agree to provide guidance and oversight as necessary to the above-named student 
regarding the conduct of his/her research. I will ensure the student’s timely requests for 
protocol modifications and/or continuing reviews, compliance with the ethical conduct of 
human participant research, and the submission of the final report. I understand that an IRB 
protocol cannot be closed until final report is submitted, and I agree that, if the student fails 




SIGNATURE: Michael Webster /    Date: 
12/7/2017  


































PROTOCOL NUMBER:  IRB-03572-2017 
RESPONSIBLE 













DATE:     
01.25.2018 EXPIRATION 




LEVEL OF RISK:  Minimal  More than Minimal  
    
TYPE OF 
REVIEW: 







 Adult Participants – Written informed consent with documentation 
(signature) 
  Adult Participants – Written informed  consent with waiver of 
documentation (signature) 
  Adult Participants – Verbal informed consent 
  Adult Participants – Waiver of informed consent  
  Minor Participants – Written parent/guardian permission with 
documentation (signature) 
  Minor Participants – Written parent/guardian permission with 
waiver of documentation (signature) 
  Minor Participants – Verbal parent/guardian permission 
  Minor Participants – Waiver of parent/guardian permission 
  Minor Participants – Written assent with documentation (signature) 
  Minor Participants – Written assent with waiver of documentation 
(signature) 
  Minor Participants – Verbal assent 
  Minor Participants – Waiver of assent 
  Waiver of some elements of consent/permission/assent 
 
 
Institutional Review Board (IRB) 
for the Protection of Human Research Participants 
 
EXPEDITED PROTOCOL APPROVAL 
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APPROVAL: This research protocol is approved as presented.   If applicable, your approved consent 
form(s), bearing the IRB approval stamp and protocol expiration date, will be mailed to you 
via campus mail or U.S. Postal Service unless you have made other arrangements with the 
IRB Administrator.  Please use the stamped consent document(s) as your copy master(s).  
Once you duplicate the consent form(s), you may begin participant recruitment.  Please 
see Attachment 1 for additional important information for researchers. 
  
COMMENTS:       
Elizabeth Ann Olphie         01.12.2018          Thank you for 
submitting an IRB application.   
Elizabeth Ann Olphie, IRB Administrator                             Date                     Please direct questions to 
irb@valdosta.edu or 229-259-5045. 
 
 
Form Revised:  06.02.16 
 




ADDITIONAL INFORMATION FOR RESEARCHERS: 
 
If your protocol received expedited approval, it was reviewed by a two-member team, or, 
in extraordinary circumstances, the Chair or the Vice-Chair of the IRB.  Although the 
expediters may approve protocols, they are required by federal regulation to report 
expedited approvals at the next IRB meeting.  At that time, other IRB members may 
express any concerns and may occasionally request minor modifications to the protocol.  In 
rare instances, the IRB may request that research activities involving participants be halted 
until such modifications are implemented.  Should this situation arise, you will receive an 
explanatory communiqué from the IRB. 
 
Protocol approvals are generally valid for one year.  In rare instances, when a protocol is 
determined to place participants at more than minimal risk, the IRB may shorten the 
approval period so that protocols are reviewed more frequently, allowing the IRB to 
reassess the potential risks and benefits to participants. The expiration date of your 
protocol approval is noted on the approval form.   You will be contacted no less than one 
month before this expiration date and will be asked to either submit a final report if the 
research is concluded or to apply for a continuation of approval.  It is your responsibility to 
submit a continuation request in sufficient time for IRB review before the expiration date.  
If you do not secure a protocol approval extension prior to the expiration date, you must 
stop all activities involving participants (including interaction, intervention, data collection, 
and data analysis) until approval is reinstated.     
 
Please be reminded that you are required to seek approval of the IRB before amending 
or altering the scope of the project or the research protocol or implementing changes in 
the approved consent process/forms.  You are also required to report to the IRB, 
 51 
through the Office of Sponsored Programs & Research Administration, any 
unanticipated problems or adverse events which become apparent during the course or 
as a result of the research and the actions you have taken.   
 
Please refer to the IRB website 
(http://www.valdosta.edu/ospra/HumanResearchParticipants.shtml ) for additional 
information about Valdosta State University’s human protection program and your 
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VALDOSTA STATE UNIVERSITY HUMAN PERFORMANCE LAB – HEALTH HISTORY 
QUESTIONNAIRE 
Name:  Date:  
Address:  City:  State: Zip:  
Cell 
Phone: 
 Home Phone:  
E-mail:  Preferred contact 
method: 
Phone E-mail 
Employer:  Highest level of 
education: 
HS BS MS Professional 
Sex: M F Date of Birth: Age:  Marital 
Status: 
Single Married 
Race: White Black Asian Hispanic Other (specify): 
Emergency 
Contact: 





 Location: Phone:  
Date/Reason for 
last visit: 
 Have you ever had a 
stress test: 
Yes No Date: 
Date/Result of Last 
Cholesterol Test: 





PERSONAL HEALTH HISTORY PRESENT 
SYMPTOMS FAMILY HEALTH HISTORY  
Have you ever had or do YOU currently 
have or have any immediate family 
been told that you have... 
PRESENT SYMPTOMS 
Do you currently have or have had in the 
last 3 months… 
FAMILY HEALTH HISTORY 
Have any immediate family or 
grandparent had… 
 NO YES  NO YES  NO YES 
Anemia   Blood in urine/stool   Angina/chest pain   
Angina/chest pain   Chest pain/discomfort   Any heart surgery   
Any heart surgery   Common cold/sinusitis   Diabetes   
Any heart trouble   Coughing of blood   Heart attack   
Arthritis/joint pain   Coughing of excretion   Heart disease   
Asthma/bronchitis   Frequent headaches   High blood pressure   
Back pain/injury   Indigestion/heartburn   High cholesterol   
Cancer   Lightheaded/dizzy   Stroke   
Diabetes   Rapid heart beat   Sudden death   
Depression   Skipped heart beats      
Disease of the arteries   Shortness of breath   TOBACCO HISTORY   
Eating disorder   Pain in 
jay/neck/arm/shoulder 
  Do you currently smoke   
Emboli(us)/phlebitis      What?   Cigarettes   
Emphysema      Cigars   
Heart attack   ALCOHOL   Pipe   
Heart murmur   Do you drink alcohol 
How much in one week 
  Chewing tobacco   
High blood pressure   Beer (can/bottle)   E-cigarettes   
High cholesterol   Wine (glasses)   Are you trying to quit?   
Hospitalizations   Hard liquor (drinks)   How much per day?   
Joint/muscle swelling    Have you ever quit?   
Osteoporosis   CAFFEINE   When?   
Stroke   How much per day?  How many years & how 
much? 
  
        




   Tea (cups)     
     Soft drinks (can/bottle)  NUTRITION/DIETARY 
PRACTICES 
  
   Energy drinks 
(can/bottle) 
  Do you refrain from 
eating beef, pork, 
poultry, and/or fish? 
  
   ALLERGIES   
   Pollen/grass   
   Medicines   
   specify  
   Foods   
   specify  
   Other  
CURRENT MEDICATIONS (PRESCRIPTION, NON-PRESCRIPTION, VITAMINS, 
SUPPLEMENTS) 
NAME REASON STARTED TAKING? HOW OFTEN? DOSAGE? 
     
     
     
     
 
 
FEMALES ONLY:     
Are you: Premenopausal_____ Perimenopausal_____ Post-menopausal_____ at age_____ 
Hormone therapy? Currently _____ Past _____ For how long? _____  
 
HOSPITALIZATIONS IN THE LAST 5 YEARS (EXCEPT NORMAL PREGNANCIES) 





LIFESTYLE AND PHYSICAL ACTIVITY 
How STRESSED do you feel in your daily life? 
(circle one)  
Very 
little 
Fairly Somewhat Most of the time All of the time 
 
Why do you want to start an exercise 















Are you currently following a weight reductions 
program?  
YES NO    
If yes, for how long and what type of program?  
 
 
How would you rate your occupational activity level (how much activity /how hard is the activity level of your job)?  
 Sedentary (computer/office work)  Light (non-sedentary office work, cashier, teacher, nursing) 
 Moderate (mail carrier, restaurant server)  Heavy/vigorous (construction, fire service, fitness instructor) 
 
OVER THE LAST 3 MONTHS, HAVE YOU REGULARLY… (Indicate those that apply and complete the corresponding questions) 
 Performed aerobic exercise (walking, jogging, swimming, cycling aerobics class, Zumba, etc.) 
 What type?  
 Days per 
week? 
 Minutes per 
week? 
 
 If you walk/jog/run, how many miles do you 
usually do? 




 Played strenuous sports (basketball, tennis, racquetball, soccer, martial arts, etc.) 
 What type?  
 Days per 
week? 





 Participated in resistance/strength/weight training (lift weights, body pump class, TRX, etc.) 
 What type?  
 Days per 
week? 




 Participated in flexibility, core strengthening, neuromotor fitness activities (yoga, Pilates, boot camp classes, etc.)  
 What type?  
 Days per 
week? 




During exercise, do you ever experience any of the following (check all that apply): 
 Uncomfortable shortness of breath  Chest pain/discomfort (does it go away 
with rest?    
YES NO 
 Lightheaded/dizzy  Bone or joint discomfort/swelling 
 Muscle pain/swelling  Other problems: 






















































Polar Heart Rate Monitor 
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APPENDIX I: 
Recruitment Poster 
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